Neuronetics, Inc. (STIM) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
This Annual Report covers the fiscal year ended December 31, 2025. Neuronetics, Inc. operates as a vertically integrated neuroscience company with two primary segments: Medical Device (sales of the NeuroStar Advanced Therapy System and treatment sessions) and Clinic Services (operations of Greenbrook Treatment Centers). The reporting period is significantly impacted by the acquisition of Greenbrook TMS Inc., completed on December 9, 2024, which transformed the company from a pure-play device manufacturer into a provider of direct patient care services.
Key Financial Metrics
| Metric | 2025 (Actual) | 2024 (Actual) | Change |
|---|---|---|---|
| Total Revenue | $149.2 million | $74.9 million | +99% |
| Gross Profit | $72.3 million | $54.2 million | +34% |
| Gross Margin | 48.5% | 72.3% | -23.8 pts |
| Net Loss | $(39.1) million | $(43.7) million | -11% (Improvement) |
| Cash and Equivalents | $28.1 million | $18.5 million | +52% |
| Long-Term Debt (Principal) | $70.0 million | $60.0 million | +16.7% |
| Operating Cash Flow | $(20.4) million | $(31.0) million | -34% (Improvement) |
Revenue Composition (2025): Clinic revenue now represents 59% of U.S. revenue ($87.0 million), up from 6% in 2024. Treatment session revenue accounts for 30% ($43.3 million), and NeuroStar system sales account for 10% ($14.3 million).
Material Changes vs. Prior Period
- Revenue Surge: Total revenue nearly doubled, driven primarily by the inclusion of Greenbrook's clinic operations ($82.5 million increase in U.S. clinic revenue). This shift diluted the overall gross margin from 72.3% to 48.5% due to the lower-margin nature of service-based clinic revenue compared to high-margin treatment session sales.
- Expense Management: Research and Development (R&D) expenses decreased 48% to $6.6 million, largely due to the absence of a $4.0 million non-cash software impairment charge recorded in 2024 and restructuring savings. General and Administrative (G&A) expenses increased 64% to $49.7 million due to the consolidation of Greenbrook's overhead.
- Debt Restructuring: The company replaced its previous Solar Capital facility with a new $90 million credit facility from Perceptive Credit Holdings in July 2024. As of year-end, $70 million was drawn. The company recorded no loss on debt extinguishment in 2025, compared to a $4.4 million loss in 2024.
Guidance, Outlook, and Risks
Management Outlook: Management anticipates continued operating losses in the near term as the company integrates Greenbrook and invests in sales and marketing. They believe current cash balances ($28.1 million) and anticipated revenues are sufficient to fund operations for at least the next 12 months. The company expects sales and marketing expenses to decrease in 2026 due to post-acquisition efficiencies, while G&A expenses may increase to support system streamlining.
Key Risks and Contingencies:
- Regulatory Investigations: The company is cooperating with a Civil Investigative Demand (CID) from the U.S. Attorney's Office for the Middle District of Florida and a similar investigation by the Michigan Attorney General regarding federal healthcare program billing practices. These investigations focus on periods prior to the Greenbrook acquisition.
- Reimbursement and Billing: The company faces risks related to billing accuracy and collections. Medicare Administrative Contractors have alleged approximately $1.3 million in reimbursements may be subject to recoupment. The company has also faced challenges collecting patient responsibility payments following the revenue cycle management integration.
- Liquidity Covenants: The Perceptive Credit Facility includes minimum net revenue and liquidity covenants. While the company amended these covenants in March 2026 to provide relief through late 2026/2027, failure to meet future covenants could trigger a default.
- Leadership Transition: CEO Keith J. Sullivan is retiring in March 2026, with Daniel Reuvers appointed as the new CEO. The effectiveness of this transition is a key operational risk.
Investor Verification Checklist
- Reimbursement Recoupment: Verify the status of the $1.3 million in potential Medicare recoupments and the outcome of the ongoing federal and state investigations into billing practices.
- Covenant Compliance: Monitor quarterly reports to ensure the company meets the amended minimum net revenue and liquidity covenants under the Perceptive Credit Facility.
- Cash Burn Rate: Track the trajectory of operating cash flow to confirm the company can maintain liquidity without further dilutive equity raises or debt refinancing.
- Integration Synergies: Assess whether the projected cost synergies from the Greenbrook acquisition are being realized, specifically regarding the reduction in sales and marketing expenses.
- Leadership Continuity: Evaluate the impact of the CEO transition on strategic execution and operational stability in early 2026.